selinexor + ibrutinib + rituximab

**selinexor + ibrutinib + rituximab** is an investigational drug combination comprising selinexor (an oral selective inhibitor of nuclear export/XPO1), ibrutinib (an oral small molecule inhibitor of Bruton’s tyrosine kinase), and rituximab (a monoclonal antibody targeting CD20 on B lymphocytes). Each agent is approved individually for hematologic malignancies, and ibrutinib + rituximab is an FDA-approved combination for certain B-cell malignancies including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)[2][4][6]. Selinexor + ibrutinib has demonstrated synergistic activity and tolerability in early-phase clinical trials for relapsed/refractory CLL and non-Hodgkin lymphoma (NHL), showing that dual BTK inhibition plus immunotherapy can induce durable responses and potentially deepen remissions[1][7]. The addition of rituximab to selinexor + ibrutinib is under research but not approved as a combination; it seeks to integrate targeted therapy (BTK inhibition) and immunotherapy (CD20 blockade) with nuclear export inhibition for improved anti-tumor efficacy.

Other names

selinexor + ibrutinib + rituximab